Nuvation Bio Inc. (NYSE:NUVB) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET
Company Participants
J.R. DeVita – Investor Relations
David Hung – Founder, President and Chief Executive Officer
Colleen Sjogren – Chief Commercial Officer
Philippe Sauvage – Chief Financial Officer
Conference Call Participants
Gregory Renza – RBC Capital Markets
Kaveri Pohlman – Clear Street
Soumit Roy – Jones Research
Michael Yee – Jefferies
Yaron Werber – TD Cowen
Operator
Good afternoon and welcome to the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call. Please be advised that today’s conference call is being recorded. [Operator Instructions] Following the formal remarks, we will open the call for questions. I would now like to turn the call over to J.R. DeVita, Executive Director of Corporate Development and Investor Relations at Nuvation Bio. Please go ahead.
J.R. DeVita
Thank you and good afternoon, everyone. Joining me on today’s call are Dr. David Hung, our Founder, President and Chief Executive Officer; Colleen Sjogren, our Chief Commercial Officer; and Philippe Sauvage, our Chief Financial Officer.
Certain statements we make during this call will be forward-looking. These include statements about taletrectinib’s expected FDA approval, U.S. commercial launch and potential benefit for patients, our commercial team’s launch readiness and our cash runway. Because such statements deal with future events that are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the U.S. Securities and Exchange Commission.
This afternoon, we released financial results for the quarter ended March 31, 2025 and provided a business update. The press release is available on the Investors section of our website at nuvationbio.com. These statements
